CompletedPhase 1LSD
Effect of Ketanserin After LSD Administration
Sponsored by University Hospital, Basel, Switzerland
NCT ID
NCT04558294
Target Enrollment
24 participants
Start Date
2020-10-16
Est. Completion
2021-09-29
About This Study
LSD (lysergic acid diethylamide) is a serotonergic (5-HT) hallucinogen widely used for recreational and/or ethnomedical purposes. LSD is thought to induce its prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. This study investigates whether an LSD experience can be attenuated and shortened using 5-HT2A receptor antagonist ketanserin administration after LSD once the psychedelic effects have established.
Conditions Studied
Interventions
- •Lysergic Acid Diethylamide
- •Ketanserin Placebo
- •Ketanserin
Eligibility
Age:25 Years - 65 Years
Healthy Volunteers:Yes
View full eligibility criteria
Inclusion Criteria: 1. Age between 25 and 65 years old 2. Sufficient understanding of the German language 3. Understanding of procedures and risks associated with the study 4. Willing to adhere to the protocol and signing of the consent form 5. Willing to refrain from the consumption of illicit psychoactive substances during the study 6. Abstaining from xanthine-based liquids and foods from the evenings prior to the study sessions to the end of the study days 7. Willing not to operate heavy machinery within 48 hours after substance administration 8. Willing to use double-barrier birth control throughout study participation 9. Body mass index between 18-29 kg/m2 Exclusion Criteria: 1. Chronic or acute medical condition 2. Current or previous major psychiatric disorder 3. Psychotic disorder or bipolar disorder in first-degree relatives 4. Hypertension (\>140/90 mmHg) or hypotension (SBP\<85 mmHg) 5. Hallucinogenic substance use (not including cannabis) more than 20 times or any time within the previous two months 6. Pregnancy or current breastfeeding 7. Participation in another clinical trial (currently or within the last 30 days) 8. Use of medication that may interfere with the effects of the study medication 9. Tobacco smoking (\>10 cigarettes/day) 10. Consumption of alcoholic beverages (\>20 drinks/week)
Study Locations (1)
Clinical Pharmacology & Toxicology, University Hospital Basel
Basel, Switzerland